NexPlasmaGen – winner of TiEQuest 2026 Medtech track pitch competition

29 May NexPlasmaGen – winner of TiEQuest 2026 Medtech track pitch competition

Montreal / May 28, 2026

NexPlasmaGen just won the 𝗧𝗶𝗘𝗤𝘂𝗲𝘀𝘁 𝟮𝟬𝟮𝟲 MedTech track competition with a prize of 15 000 CAD!

🌟 𝗠𝗲𝗱𝗧𝗲𝗰𝗵 𝗧𝗿𝗮𝗰𝗸 𝗪𝗶𝗻𝗻𝗲𝗿
Dr. Valérie Léveillé — Founder & CEO, NexPlasmaGen Leveille
Advancing breakthrough cancer innovation through cold plasma technology,- bringing hope for better patient outcomes and redefining the future of precision treatment. 🩺🔬✨

NexPlasmaGen gives its heartfelt gratitude to the 𝗠𝗲𝗱𝗧𝗲𝗰𝗵 𝗝𝘂𝗱𝗴𝗲𝘀 for their time, expertise, and thoughtful deliberation:
• Ken Spears, Boston Scientific
• Shiraz Patel, Halo Health
• Alex Norman, N49P
• Peyvand Melati, Axion Fund
• Andrew Opala, Preference Capital
𝘠𝘰𝘶𝘳 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘢𝘯𝘥 𝘤𝘰𝘮𝘮𝘪𝘵𝘮𝘦𝘯𝘵 𝘤𝘰𝘯𝘵𝘪𝘯𝘶𝘦 𝘵𝘰 𝘦𝘭𝘦𝘷𝘢𝘵𝘦 𝘵𝘩𝘦 𝘦𝘯𝘵𝘳𝘦𝘱𝘳𝘦𝘯𝘦𝘶𝘳𝘪𝘢𝘭 𝘦𝘤𝘰𝘴𝘺𝘴𝘵𝘦𝘮.

Huge thanks to the event’s sponsor for the valuable time and contribution :
Baylis Medical Technologies, Kris Shah, Frank Baylis, ICICI Bank Canada, Himadar Maddipatla, Niloy Nath, Brampton Innovation District, Denise McClure, Tara Hunter, Suvid Ajmera, City of Toronto, Susana Vaz, Clare Barnett, Tangentia Ventures, Vijay Thomas, Scotia Wealth Management, Manny Gill, Gautam Mohorikar, Vijay Parmar, CPA, CA, Frank Pantazopoulos, MBA, CFA, Ownr, Marco Morelli, MBA, BDO, Alim Bhayani, CPA, CA, Kiwi Charge, Abdel Ali, MBA, CFA

Special thanks to TechTO Megha Kandoi, Wil costigan and team for supporting and building this ecosystem
Upasana Sharma, Mahendra Naik, Vijay Thomas, Kanchan Kumar Jey Narayanan Sokkappan Zahin Hussain Justin Lo, Vinay Dora K, Vijay Menon Sai Charantimath Manaswi Tiple Nisarg Lakhmani

hashtag#TiEQuest2026 hashtag#TiEToronto hashtag#Winners hashtag#Founders hashtag#ReshapingtheWorld

ABOUT NEXPLASMAGEN

NexPlasmaGen converges the emerging field of cold plasma biotechnology towards personalized cancer treatment. We develop high-precision cold plasma systems that destroy cancer cells while sparing the healthy tissue. The first application of NexPlasmaGen is the treatment of breast cancer, followed by skin and lung cancer. Its patented cold plasma medical device has the potential to reduce the rate of cancer recurrence as well as side effects and toxicity of the standard of care for the benefit of patients.

Contact :

Dr. Valérie Léveillé, ing., M.Sc.A., CEO/Founder

Tel. : 1-514-229-9458

Email : valerie.leveille@nexplasmagen.com

Website : https://nexplasmagen.com/